Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
No Thumbnail Available
Identifiers
Date
2021-11-30
Authors
Valldeoriola, Francesc
Catalán, María José
Escamilla-Sevilla, Francisco
Freire, Eric
Olivares, Jesús
Cubo, Esther
García, Diego Santos
Calopa, Matilde
Martínez-Martín, Pablo
Parra, Juan Carlos
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P